MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Natera, Inc.

< Previous 1 2 3 4 5 Next >
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Report its First Quarter Results on May 8, 2025
From Natera, Inc.
Via Business Wire
Tickers NTRA
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
From Natera, Inc.
Via Business Wire
Tickers NTRA
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Fourth Quarter and Full Year 2024 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025
From Natera, Inc.
Via Business Wire
Tickers NTRA
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces National Commercial Coverage for its Fetal RhD NIPT
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present New Data at the 2025 ASCO GI Symposium
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
Tickers NTRA
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
From Natera, Inc.
Via Business Wire
Tickers NTRA
Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Issues Statement on Guardant Health Litigation
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Reports Third Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
Tickers NTRA
Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Tickers NTRA
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story